These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33085959)

  • 21. Evaluation of new medicines in Spain and comparison with other European countries.
    Epstein D; Espín J
    Gac Sanit; 2020; 34(2):133-140. PubMed ID: 31027840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The novelties of the regulation on health technology assessment, a key achievement for the European union health policies.
    Pisapia A; Banfi G; Tomaiuolo R
    Clin Chem Lab Med; 2022 Jul; 60(8):1160-1163. PubMed ID: 35624072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DEVELOPMENT OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA.
    Scintee SG; Ciutan M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):371-375. PubMed ID: 28436346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties.
    Bojke L; Grigore B; Jankovic D; Peters J; Soares M; Stein K
    Pharmacoeconomics; 2017 Sep; 35(9):867-877. PubMed ID: 28616775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
    Allen N; Liberti L; Walker SR; Salek S
    Front Pharmacol; 2017; 8():384. PubMed ID: 28713265
    [No Abstract]   [Full Text] [Related]  

  • 30. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health technology assessment for medical devices in Europe. What must be considered.
    Siebert M; Clauss LC; Carlisle M; Casteels B; de Jong P; Kreuzer M; Sanghera S; Stokoe G; Trueman P; Lang AW;
    Int J Technol Assess Health Care; 2002; 18(3):733-40. PubMed ID: 12391964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit.
    Halmesmäki E; Pasternack I; Roine R
    Health Res Policy Syst; 2016 Apr; 14():25. PubMed ID: 27044400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health technology assessment and policy from the economic perspective.
    Rutten F
    Int J Technol Assess Health Care; 2004; 20(1):67-70. PubMed ID: 15176179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction: health technology assessment and the European Union.
    Banta D; Oortwijn W
    Int J Technol Assess Health Care; 2000; 16(2):299-302. PubMed ID: 10932410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
    Kawalec P; Malinowski KP; Trąbka W
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review.
    Löblová O; Trayanov T; Csanádi M; Ozierański P
    Value Health; 2020 Jan; 23(1):3-9. PubMed ID: 31952670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.